Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
BALCHEM CORP
Bear Case (25th pct.)
-58.2% vs price
Base Case (Median)
-53.3% vs price
Bull Case (75th pct.)
-46.9% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $71.95 | -56.8% | High (40%) |
| PE Comparable | $90.19 | -45.9% | Medium (25%) |
| Growth Trajectory DCF | $86.58 | -48.0% | Medium (20%) |
| Graham Number | $67.19 | -59.7% | Medium (30%) |
| EV/EBITDA | $77.85 | -53.3% | Medium (20%) |
| EV/FCF | $108.57 | -34.8% | Medium (20%) |
| Earnings Power Value | $53.78 | -67.7% | Medium (50%) |
Based on 7 out of 7 methods, BCPC appears overvalued at the current price of $166.56. The base case fair value of $77.85 implies 53.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.